Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · VENUSREM

VENUS REMEDI

HealthcarePharmaceuticals & Biotechnology₹1937 cr market cap
₹1501.60 ▲ +3.2% today As of 19 Nov 2026
52-week low ₹537.7552-week high ₹1947.00

-25.3% from the 52-week high · +170.6% above the low

Venus Remedies Ltd. engages in the manufacture and trade of pharmaceutical products. The company is headquartered in Panchkula, Haryana and currently employs 998 full-time employees. The firm is a global injectable manufacturer, possessing a wide product basket catering to therapeutic segments of anti-infective specially in antimicrobial resistance (AMR), oncology, skin and wound care and pain management. The firm operates in the Pharmaceutical Formulation segment. The company manufactures products catering to the critical care and super specialty segments. The firm's product portfolio includes formulations such as injectables, tablets, and topical preparations. The firm offers solutions in the domains of antimicrobial resistance (AMR), oncology, skin & wound care, neurology, anticoagulants, pain management, herbal portfolio and disinfectants. Its focus therapy areas include medicine, surgery, neuro and orthopedics. The Company’s brands include Potentox, Vancoplus Combi, Tobracef, Supime, Zydotum, Neurotol, Trois, Septiloc, Mucomelt, Ventaful and Nervolize. The company has three manufacturing facilities.

The short version. VENUS REMEDI reported revenue of ₹219 crore for Sep 2026, up 13.5% from a year earlier. Net profit was ₹26 crore (up 30.0% year on year). Return on equity was 15.5% in Mar 2026. Promoter holding was 41.76% in Sep 2026, up 0.00 points over 8 quarters.

1 · The price

How has the stock traded?

VENUS REMEDI trades 25.3% below its 52-week high and 170.6% above its 52-week low.

Change over period: —

1M-8.7%
3M-17.8%
6M+39.6%
1Y+162.2%

2 · The business

Is it growing?

Sales, year on year+13.5%

Sep 2026 revenue of ₹219 cr.

Profit, year on year+30.0%

Sep 2026 net profit of ₹26 cr.

Net margin11.7%

1.3 pts higher than a year earlier.

3-year growth57.0% profit

Revenue compounded at 11.4% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue219179259180193132195177
Net profit2623472620102120
Net margin %11.712.818.314.210.47.310.811.1
EPS (₹)19.1917.1835.5319.1415.067.1815.7114.66

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2018
Revenue770648601556599548341372
Net profit1034528274162-10-31
Net margin %13.47.04.74.86.811.3-2.9-8.2
EPS (₹)76.8933.921.3219.8830.4750.04-8.1-24.87

3 · The quality

How well does it turn capital into profit?

Return on equity was 15.5% in Mar 2026; debt to equity is 0.00.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %15.58.15.85.8
Return on capital %19.412.48.27.4
EBITDA margin %20.414.111.612.5
Net margin %13.16.84.74.7

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR11.4%6.6%
Profit CAGR57.0%10.7%
Debt to equity0.00
Interest cover3354.8x
Current ratio2.44
P/E ratio15.9

4 · The owners

Who holds it, and are they adding?

Promoter holding41.76%

Unchanged over 8 quarters.

Foreign institutions3.14%

Up 2.03 pts over 8 quarters.

Domestic institutions0.74%

Up 0.74 pts over 8 quarters.

Mutual fund schemes2

+0 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter41.7641.7641.7641.7641.7641.7641.7641.760.0
FII1.111.342.241.862.262.82.923.14+2.03
DII000.110.751.031.20.890.74+0.74
Public57.1356.955.8955.6354.9654.2454.4354.36-2.77

Mutual fund holdings · Oct 2026

2 schemes hold this stock

2 the month before.

  • Motilal Oswal BSE Healthcare ETF0.06% of NAV
  • Bandhan BSE Healthcare Index Fund0.06% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for VENUS REMEDI are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about VENUS REMEDI

What is the VENUS REMEDI share price?

VENUS REMEDI (VENUSREM) last closed at ₹1,501.60, up 3.2% on the day. Its 52-week range is ₹537.75 to ₹1,947.00.

What is the market cap of VENUS REMEDI?

VENUS REMEDI has a market capitalisation of about ₹1,937 crore. Its price-to-earnings ratio is 15.9.

How are VENUS REMEDI's latest results?

VENUS REMEDI reported revenue of ₹219 crore for Sep 2026, up 13.5% from a year earlier. Net profit was ₹26 crore (up 30.0% year on year). Return on equity was 15.5% in Mar 2026. Promoter holding was 41.76% in Sep 2026, up 0.00 points over 8 quarters.

Who owns VENUS REMEDI?

As of Sep 2026, shareholding was: Promoter 41.76%, FII 3.14%, DII 0.74%, Public 54.36%.

How many mutual funds hold VENUS REMEDI?

2 mutual fund schemes held VENUS REMEDI in October 2026. That compares with 2 the month before.

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.